

DRUG PRIOR AUTHORIZATION COMMITTEE

September 16, 2004
TENTATIVE AGENDA

10:00 - 10:05	Welcome, Announcements and Introductions	Henry Petry Chairman
10:05 - 10:15	Minutes Review	Discussion/ Approval
10:15- 11:30	Pharmacy Program/ Budget Update	George Oestreich/ Andrew Haslag
11:30 - 11:35	DUR Update	Jayne Zemmer

Old Business

11:35 - 12:05	Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	George Oestreich
---------------	--	------------------

New Business

12:05 – 12:20	New Drug/Product Reviews	
	a. Proposed Actions (See website and Attached Summary)	George Oestreich/ Rhonda Driver
	i. Open Access	
	ii. Clinical Edit/Step Therapy	
	iii. Prior Authorization	

12:20-1:45	<i>Proposed New Program Actions of Existing Products</i>	George Oestreich/ Rhonda Driver
------------	--	------------------------------------

- a. **Clinical Edits**
- i. **Triptans (edit change)**
- Discussion
 - Public Hearing
 - Decision
- ii. **DMARD's (edit change)**
- Discussion
 - Public Hearing
 - Decision
- b. **Prior Authorization Edit**
- i. **Accutane (Isotretinoin) (edit change)**
- Discussion
 - Public Hearing
 - Decision
- c. **Fiscal Edit**
- i. **Dose Optimization Addition**
- Discussion
 - Public Hearing
 - Decision
- d. **Preferred Drug List (PDL)**
- i. **ACE Inhibitors**
- Discussion
 - Public Hearing
 - Decision
- ii **ACE Inhibitors Diuretic Combinations**
- Discussion
 - Public Hearing
 - Decision
- iii. **ACE Inhibitor Calcium Channel Blockers**
- Discussion
 - Public Hearing
 - Decision
- iv. **Angiotensin Receptor Blockers**
- Discussion
 - Hearing
 - Decision

v. Angiotensiin Receptor Blockers & Diuretics

- Discussion
- Public Hearing
- Decision

vi. Narcotics – Long Acting

- Discussion
- Public Hearing
- Decision

vii. Bone Ossification Suppression Agents

- Discussion
- Public Hearing
- Decision

viii. Nasal Steroids

- Discussion
- Public Hearing
- Decision

ix. 2nd Generation Antihistamines

- Discussion
- Public Hearing
- Decision

x. 2nd Generation Antihistamines/Decongestant Combinations

- Discussion
- Public Hearing
- Decision

e. Discussion Items

i. Preferred Drug List / Process discussion

ii. Therapeutic classes/Phase IV

To be announced at the meeting.

1:45

LUNCH

2:00-2:10

Physician Inquiry

Allison Lauf/Mary Heet

2:10-2:20

Drug Utilization Reports

*Informal comments will be accepted from members of the audience at various points in the agenda.
Times noted are approximate, Agenda may move more quickly*

Executive Session

2:20-2:25

Minutes Review

Discussion/Approval

2:25-3:00

Case Reviews

Allison Lauf/Mary Heet

NEXT MEETING: DECEMBER 16, 2004